Last reviewed · How we verify
Candesartan Cilexetil 32mg
Candesartan Cilexetil 32mg, marketed by Pharmtechnology LLC, is an established product in the cardiovascular segment with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and market presence, which provides a stable revenue stream. The primary risk is the potential increase in generic competition following the patent expiry in 2028.
At a glance
| Generic name | Candesartan Cilexetil 32mg |
|---|---|
| Also known as | The test product, Atacand |
| Sponsor | Pharmtechnology LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg (PHASE1)
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- CAndesartan vs LIsinopril Effects on the BRain (PHASE2)
- The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions (PHASE1)
- Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy (PHASE3)
- Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression (PHASE4)
- CKD-330 Drug-Drug Interaction Study (Candesartan) (PHASE1)
- CKD-330 Drug-Drug Interaction Study (Amlodipine) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candesartan Cilexetil 32mg CI brief — competitive landscape report
- Candesartan Cilexetil 32mg updates RSS · CI watch RSS
- Pharmtechnology LLC portfolio CI